PublishedOctober 18, 2021COVID-19DRUGSVACCINES Pharmaceutical company Merck applied on October 11 for FDA emergency use authorization for its oral antiviral COVID-19 drug, molnupiravir. In this Q&A, Carl Dieffenbach, PhD, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, and Joshua Sharfstein, MD, talk about the development of the medication, how soon couldContinue reading “Molnupiravir: The Game-Changing Antiviral Pill for COVID-19?”
A Bird's Eye View of Fashion, Food, Travel, Culture, Beverage and Curiosity 